NLS Pharmaceutics AG
NASDAQ:NLSP
4.15 (USD) • At close November 7, 2024
Overzicht | Financiële gegevens
Cijfers zijn in miljoenen (behalve de cijfers per aandeel en de ratio's) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Omzet
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Kosten van de omzet
| 0.011 | 0.011 | 0.01 | 0 | 0 | 0 | 0 |
| Brutowinst
| -0.011 | -0.011 | -0.01 | 0 | 0 | 0 | 0 |
| Brutowinstmarge
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Onderzoek- en ontwikkelingskosten
| 5.908 | 8.977 | 5.919 | 0.1 | 1.702 | 1.437 | 4.325 |
| Algemene en administratieve kosten
| 5.899 | 0.007 | 0.006 | 0.002 | 3.299 | 2.012 | 1.442 |
| Verkoop- en marketingkosten
| -0.011 | 6.488 | 5.925 | 2.198 | 2.492 | 0 | 0 |
| Verkoop-, algemene en administratieve kosten
| 5.899 | 6.494 | 5.931 | 2.2 | 2.495 | 2.012 | 1.442 |
| Overige kosten
| 0 | 0.01 | -0.017 | -0.328 | 0 | -0.629 | 0 |
| Bedrijfskosten
| 11.807 | 15.471 | 11.851 | 2.299 | 4.197 | 3.449 | 5.767 |
| Bedrijfsresultaat
| -11.807 | -15.482 | -11.861 | -2.299 | -4.197 | -3.449 | -5.767 |
| Bedrijfsresultaat ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Totaal overige inkomsten en kosten netto
| -0.365 | -1.013 | -0.085 | -0.562 | -1.25 | -0.629 | -0.89 |
| Inkomen voor belasting
| -12.172 | -16.496 | -11.946 | -2.861 | -5.447 | -5.147 | -6.657 |
| Inkomen voor belasting ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Belastingkosten
| 0 | 0 | -0.227 | -0.002 | -0.004 | 1.698 | -0.006 |
| Nettowinst
| -12.172 | -16.496 | -11.946 | -2.861 | -5.447 | -5.147 | -6.657 |
| Nettowinstmarge
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| WPA (Winst Per Aandeel)
| -0.32 | -0.84 | -0.81 | -0.59 | -0.49 | -0.44 | -0.57 |
| Verwaterde WPA
| -0.32 | -0.84 | -0.81 | -0.59 | -0.49 | -0.44 | -0.57 |
| EBITDA
| -11.796 | -15.471 | -11.851 | -2.299 | -4.197 | -3.449 | -5.767 |
| EBITDA ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |